Effect of Subcutaneous Tocilizumab on Mortality in Patients With COVID-19: A Meta-analysis of Retrospective Cohort StudiesCOVID-19 환자의 사망률에 대한 피하 토실리주맙의 효과: 후향적 코호트 연구의 메타 분석Comment Published on 2021-07-272022-09-12 Journal: American journal of therapeutics [Category] SARS, 진단, [키워드] Effect Subcutaneous [DOI] 10.1097/MJT.0000000000001434 PMC 바로가기 [Article Type] Comment
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trialReview Published on 2021-07-102022-10-04 Journal: International immunopharmacology [Category] 임상, 치료제, [키워드] ABG, Atrial blood gas Analysis Arbidol assigned Chest CT scans Clinical improvement clinical trial Committee conducted Control control group control groups COVID-19 COVID-2019, Coronavirus Disease 2019 Cox regression model dose effective Effectiveness Efficacy Ethics evaluate GCS, Glasgow Coma Scale hazard Hospitalized hospitalized patient HR, hazard ratio ICU, Intensive care unit Infection injection Intervention intervention group ITT population legally authorized representatives LFT, liver function test median Medical Sciences moderate moderate-severe Mortality non-ICU patient Open-label participant Patient positive positive RT-PCR Prognosis Randomized randomized clinical trial Randomly Ratio receive Registered Result SARS-CoV-2 SARS-CoV-2, severe acute respiratory syndrome coronavirus2 severe COVID-19 Severe patient single-center statistically significant statistically significant difference Subcutaneous time treat treated Treatment treatment group Trial TTCI TTCI, Time to clinical improvement two group umifenovir university VBG, Venous blood gas [DOI] 10.1016/j.intimp.2021.107969 PMC 바로가기 [Article Type] Review
Pneumomediastinum and Subcutaneous Emphysema in an Adult Male From Nepal Infected With COVID-19Infectious Disease Published on 2021-07-102022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Antibiotics Complication condition Conservative management COVID-19 emphysema highlight hospital infected with COVID-19 intubation male mechanical ventilation mediastinal emphysema Nepal Pneumomediastinum Pneumothorax Remdesivir reported Respiratory distress syndrome Subcutaneous [DOI] 10.7759/cureus.16306 PMC 바로가기 [Article Type] Infectious Disease
Subcutaneous Emphysema and Pneumomediastinum Following Non-invasive Ventilation in a Patient With Severe COVID-19 DiseaseInternal Medicine Published on 2021-06-302022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome caused Complication coronavirus COVID-19 Early detection etiology Factor fatal complication healthy high mortality rate incidence Invasive mechanical ventilation Lung injury male mechanical ventilation NIMV Non-invasive non-invasive ventilation observation outcome Pathogenesis Patient Pneumomediastinum positive potential risk receiving SARS-CoV-2 SARS-CoV-2 pneumonia severe coronavirus disease Subcutaneous subcutaneous emphysema tested treated while [DOI] 10.7759/cureus.16051 PMC 바로가기 [Article Type] Internal Medicine
Intravenous administration of anakinra in children with macrophage activation syndromeShort Report Published on 2021-06-292022-10-29 Journal: Pediatric Rheumatology Online Journal [Category] Coronavirus, MERS, SARS, [키워드] addition Administered administration anaphylaxis AST children COVID-19 criteria Critically ill patient Cytokine storm syndrome dysfunction edema ferritin fibrinogen finding hospitalized patient Inflammatory inhibitor Injections intravenous Intravenous administration intravenously juvenile idiopathic arthritis macrophage activation syndrome male MIS-C neurological Platelet reaction recent secondary hemophagocytic lymphohistiocytosis sHLH SLE Subcutaneous syndrome systemic lupus erythematosus therapeutic option treat Treatment [DOI] 10.1186/s12969-021-00585-3 PMC 바로가기 [Article Type] Short Report
Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19Roux-en-Y 위 우회는 피하 백색 지방 조직에서 안지오텐신 전환 효소 2(ACE2) 유전자 발현을 하향 조절합니다: 심각한 COVID-19에 대한 추정 보호 메커니즘Article Published on 2021-06-012022-09-11 Journal: Obesity surgery [Category] SARS, 유전자 메커니즘, [키워드] ACE-2 ACE2 ACE2 gene acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adipose Adipose tissue Against age angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 Bariatric surgery benefit biopsies biopsy BMI bypass Control coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 expressed expression Gastric Gene Expression Omnibus GEO logFC Microarray microarray data obese obesity progression protective mechanism receptor SARS-CoV-2 searched severe acute respiratory syndrome Coronavirus severe coronavirus disease Sex significant decrease significantly lower Subcutaneous subjects SWAT tissue white women [DOI] 10.1007/s11695-021-05271-7 PMC 바로가기 [Article Type] Article
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19피하 토실리주맙을 사용한 인터루킨-6 수용체 차단은 COVID-19 환자의 응고 활성을 개선합니다Article Published on 2021-01-012022-09-12 Journal: European journal of internal medicine [Category] 진단, [키워드] 95% confidence interval 95%CI activate activated Admission age Analysis Anticoagulants blockade Blood coagulation C-reactive protein change Coagulation Coagulation parameters contribute COVID-19 COVID-19 pathogenesis COVID-19 patient Critical cytokine D-dimer level death develop dose enrolled evaluate the effect fibrinogen humanized monoclonal antibody hypercoagulable hyperinflammation Hyperinflammatory IMPROVE increase in Inflammation interleukin-6 interleukin-6 receptor interquartile range laboratory-confirmed moderate occurred Occurrence parameter Patient patients with COVID-19 Platelet Pneumonia Prophylactic Prophylaxis Prothrombin time receiving receptor reduction reduction in Respiratory function Standard of care Subcutaneous subcutaneous dose sustained therapeutic thromboembolic complications Thromboprophylaxis thrombosis Tocilizumab Treatment were measured [DOI] 10.1016/j.ejim.2020.10.020 PMC 바로가기 [Article Type] Article
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusionSARS-CoV-2 감염 환자의 토실리주맙 투여: 피하 주사 대 정맥 주입Comment Published on 2021-01-012022-09-12 Journal: Journal of medical virology [Category] SARS, 진단, [키워드] Abstract administration COVID-19 Cytokine storm syndrome injection intravenous patients with SARS-CoV-2 pharmacokinetic Subcutaneous Tocilizumab [DOI] 10.1002/jmv.26124 PMC 바로가기 [Article Type] Comment
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients중증 코로나19 환자에서 사이토카인 폭풍 증후군에 이차적으로 발생하는 급성 호흡곤란 증후군 치료를 위한 고용량 피하 아나킨라Article Published on 2020-12-012022-09-12 Journal: Journal of autoimmunity [Category] SARS, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome adverse effect age Aminotransferase Anakinra ARDS Cohort cohort of patient cohort study cohorts Combination COVID-19 COVID-19 patient CRP CSS Cytokine storm syndrome D-dimer develop distress dose elevated exhibited exhibiting ferritin group hyperinflammation hyperinflammatory state IL-1 IL-6 IL-6 inhibitor in both group Infection Inflammatory inhibition initial intravenous males median multi-organ failure non-responder outcome paO2/fiO2 PaO2/FiO2 ratio Patient patients patients treated produced propensity score matching reduction Resolution Respiratory function respond SARS-CoV2 severe COVID-19 significantly increased single dose Subcutaneous syndrome TCZ therapy Tocilizumab treat treated Treatment Two patient was selected was used [DOI] 10.1016/j.jaut.2020.102537 PMC 바로가기 [Article Type] Article
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial심각하고 치명적인 COVID-19가 있는 성인의 피하 토실리주맙: 전향적 공개 표지 비통제 다기관 시험Clinical Trial Published on 2020-12-012022-09-12 Journal: International immunopharmacology [Category] MERS, SARS, 임상, 진단, [키워드] added all-cause mortality rate Antiviral approved body temperature changes in clinical parameter concerning coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patients Critical Critical disease dose early stage Endpoint enrolled immunomodulator immunomodulatory IMPROVE in both group interleukin interleukin 6 Laboratory male Most patient multicenter Multicenter trial occurred Open-label oral temperature oxygen saturation oxygen-support Oxygenation Patient patients died Potential reduce reported required Respiratory failure respiratory rate risk of death Serious Adverse Event Seven Severe patient severe patients Significant significantly standard care Subcutaneous subjects Therapeutic approach therapy Tocilizumab tocilizumab administration variable [DOI] 10.1016/j.intimp.2020.107102 PMC 바로가기 [Article Type] Clinical Trial